REFERENCES
- Curtis J A, Patrick D L. The assessment of health status among patients with COPD. Eur Respir J 2003; 21: 36s–45s, Suppl. 41[CSA]
- Feenstra T L, van Genugten M L, Hoogenveen R T, Wouters E F, Rutten-van Molken M P. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in The Netherlands. Am J Respir Crit Care Med 2001; 164: 590–596, [INFOTRIEVE], [CSA]
- Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease—Updated 2005. http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989 (accessed February 2006)
- Ramsey S D, Sullivan S D. The burden of illness and economic evaluation for COPD. Eur Respir J 2003; 21: 29s–35s, Suppl. 41[CROSSREF], [CSA]
- British Thoracic Society. COPD Consortium, http://www.brit-thoracic.org.uk/copd/pubs_frameset.html (accessed February 2006)
- European Respiratory Society. European Lung White Book. European Respiratory Society Publications, Sheffield, UK 2003
- US Department of Health and Human Services—National Institutes of Health, http://www.nhlbi.nih.gov/health/public/lung/other/copd_fact.pdf (accessed February 2006)
- Rennard S, Decramer M, Calverley P M, Pride N B, Soriano J B, Vermeire P A, Vestbo J. Impact of COPD in North America and Europe in 2000; subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002; 20: 799–805, [INFOTRIEVE], [CROSSREF], [CSA]
- Seemungal T AR, Donaldson G C, Paul E A, Bestall J C, Jeffries D J, Wedzicha J A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–1422, [INFOTRIEVE], [CSA]
- Spencer S, Calverley P MA, Burge P S. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698–702, [INFOTRIEVE], [CROSSREF], [CSA]
- Spencer S, Jones P W. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589–593, [INFOTRIEVE], [CROSSREF], [CSA]
- De Leon S F, Thurston G D, Ito K. Contribution of respiratory disease to nonrespiratory mortality associations with air pollution. Am J Respir Crit Care Med 2003; 167: 1117–1123, [INFOTRIEVE], [CROSSREF], [CSA]
- Schwartz J. Air pollution and hospital admissions for heart disease in eight U.S. counties. Epidemiology 1999; 10: 17–22, [INFOTRIEVE], [CROSSREF], [CSA]
- He J, Vupputuri S, Allen K, Prerost M R, Hughes J, Whelton P K. Passive smoking and the risk of coronary heart disease. A meta-analysis of epidemiological studies. N Eng J Med 1999; 340: 920–926, [CROSSREF], [CSA]
- Law M R, Morris J K, Wald N J. Environmental tobacco smoke exposure and ischemic heart disease: an evaluation of the evidence. BMJ 1997; 315: 973–980, [INFOTRIEVE], [CSA]
- Sin D D, Wu L, Anderson J A, Anthonisen N R, Buist A S, Burge P S, Calverley P M, Connett J E, Lindmark B, Pauwels R A, Postma D S, Soriano J B, Szafranski W, Vestbo J. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992–997, [INFOTRIEVE], [CROSSREF], [CSA]
- Camilli A E, Robbins D R, Lebowitz M D. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991; 133: 795–800, [INFOTRIEVE], [CSA]
- Hansell A L, Walk J A, Soriano J B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003; 22: 809–814, [INFOTRIEVE], [CROSSREF], [CSA]
- Wise R A, McGarvey L P, John M, Anderson J A, Zvarich M T. Reliability of cause-specific mortality adjudication in a COPD clinical trial. American Thoracic Society Annual Meeting, San Diego, May, 19–242006, A120
- Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 26400–2646, [CROSSREF], [CSA]
- Curkendall S M, Deluise C, Jones J K, Lanes S, Stang M R, Goehring E, Jr., She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63–70, [INFOTRIEVE], [CROSSREF], [CSA]
- Sidney S, Sorel M, Quesenberry C P, Jr., DeLuise C, Lanes S, Eisner M D. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068–2075, [INFOTRIEVE], [CROSSREF], [CSA]
- Dankner R, Goldbourt U, Boyko V, Reicher-Reiss H. Predictors of cardiac and non-cardiac mortality among 14,697 patients with coronary heart disease. Am J Cardiol 2003; 91: 121–127, [INFOTRIEVE], [CROSSREF], [CSA]
- Hole D J, Watt G C, Davey-Smith G, Hart C L, Gillis C R, Hawthorne V M. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Br Med J 1996; 313: 711–715, [CSA]
- Schunemann H J, Dorn J, Grant B J, Winkelstein W, Jr., Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000; 118: 656–664, [INFOTRIEVE], [CROSSREF], [CSA]
- Engstrom G, Lind P, Hedblad B, Wollmer P, Stavenow L, Janzon L, Lindgarde F. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002; 106: 2555–2560, [INFOTRIEVE], [CROSSREF], [CSA]
- Strachan D P. Commentary: predicting and preventing premature mortality. BMJ 1996; 313: 715–716, [CSA]
- Kjoller E, Kober L, Iversen K, Torp-Pedersen C, Trace Study Group. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. Eur J Heart 2004; 6: 71–77, [CROSSREF], [CSA]
- Anthonisen N R, Connett J E, Enright P L, Manfreda J, Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333–339, [INFOTRIEVE], [CROSSREF], [CSA]
- Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth O A, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon J L, Nieminen M S, Pierard L, Remme W J, Task Froce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115–1140, [INFOTRIEVE], [CROSSREF], [CSA]
- Rutten F H, Moons K G, Cramer M J, Grobbee D E, Zuithoff N P, Lammers J W, Hoes A W. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross-sectional diagnostic study. BMJ 2005; 331: 1379, [INFOTRIEVE], [CROSSREF], [CSA]
- Rutten F H, Cramer M J, Grobbee D E, Sachs A P, Kirkels J H, Lammers J W, Hoes A W. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887–1894, [INFOTRIEVE], [CROSSREF], [CSA]
- Hogg J C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709–721, [INFOTRIEVE], [CROSSREF], [CSA]
- Hogg J C, Chu F, Utokaparch S, Woods R, Elliott W M, Buzatu L, Cherniack R M, Rogers R M, Sciurba F C, Coxson H O, Pare P D. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645–2653, [INFOTRIEVE], [CROSSREF], [CSA]
- Bhowmik A, Seemungal T A, Sapsford R J, Wedzicha J A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114–120, [INFOTRIEVE], [CROSSREF], [CSA]
- Celli B R, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946, [INFOTRIEVE], [CSA]
- Maestrelli P, Saetta M, Di Stefano A, Calcagni P G, Turato G, Ruggieri M P, Roggeri A, Mapp C E, Fabbri L M. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646–1652, [INFOTRIEVE], [CSA]
- Saetta M, Di Stefano A, Maestrelli P, Turato G, Mapp C E, Pieno M, Zanguochi G, Del Prete G, Fabbri L M. Airway eosinophilia and expression of interleukin-5 in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy 1996; 26: 766–774, [INFOTRIEVE], [CROSSREF], [CSA]
- Zhu J, Qiu Y S, Majumdar S, Gamble E, Matin D, Turato G, Fabbri L M, Barnes N, Saetta M, Jeffery P K. Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001; 164: 109–116, [INFOTRIEVE], [CSA]
- Santos S, Peinado V I, Ramirez J, Morales-Blanhir J, Bastos R, Roca J, Rodriguez-Roisin R, Barbera J A. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1250–1256, [INFOTRIEVE], [CROSSREF], [CSA]
- Gan W Q, Man S F, Senthilselvan A, Sin D D. Association between chronic onstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574–580, [INFOTRIEVE], [CROSSREF], [CSA]
- Sin D D, Man S F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases?. Circulation 2003; 107: 1514–1519, [INFOTRIEVE], [CROSSREF], [CSA]
- Wedzicha J A, Seemungal T A, MacCallum P K, Paul E A, Donaldson G C, Bhowmik A, Jeffries D J, Meade T W. Acute exacerbations of COPD are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210–215, [INFOTRIEVE], [CSA]
- Mannino D M, Ford E S, Redd S C. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003; 114: 758–762, [INFOTRIEVE], [CROSSREF], [CSA]
- Ballantyne C M, Hoogeveen R C, Bang H, Coresh J, Folsom A R, Chambless L E, Myerson M, Wu K K, Sharrett A R, Boerwinkle E. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Aatherosclerosis Risk in Communities (ARIC) Study. Circulation 2004; 109: 837–842, [INFOTRIEVE], [CROSSREF], [CSA]
- Blake G J, Ridker P M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. Am Coll Cardiol 2003; 41(4 Suppl. S)37S–42S, [CROSSREF], [CSA]
- Blake G J. Inflammatory biomarkers of the patient with myocardial insufficiency. Curr Opin Crit Care 2003; 9: 369–374, [INFOTRIEVE], [CROSSREF], [CSA]
- Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht H J, AtheroGene Investigators. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24–30, [INFOTRIEVE], [CROSSREF], [CSA]
- Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore J R, Pepys M B. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000; 321: 199–204, [INFOTRIEVE], [CROSSREF], [CSA]
- Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T, Pyorala K. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-α in the prognostic classification of unstable angina pectoris. Ann Med 2001; 33: 37–47, [INFOTRIEVE], [CSA]
- Ridker P M, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor–alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149–2153, [INFOTRIEVE], [CSA]
- Ridker P M, Rifai N, Rose L, Buring J E, Cook N R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–1565, [INFOTRIEVE], [CROSSREF], [CSA]
- Danesh J, Wheeler J G, Hirschfield G M, Eda S, Eiriksdottir G, Rumley A, Lowe G D, Pepys M B, Gudnason V. C-reactive protein and other circulating markers of inflammation in the production of coronary heart disease. N Engl J Med 2004; 350: 1387–1397, [INFOTRIEVE], [CROSSREF], [CSA]
- Ridker P M, Koenig W, Fuster V. C-reactive protein and coronary heart disease. N Engl J Med 2004; 351: 295–298, [INFOTRIEVE], [CROSSREF], [CSA]
- Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169: 203–214, [INFOTRIEVE], [CROSSREF], [CSA]
- Kinlay S, Selwyn A P. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 2003; 91: 9B–13B, Suppl. 4A[INFOTRIEVE], [CSA]
- Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001; 88(Suppl. 8A)10K–15K, [INFOTRIEVE], [CSA]
- Zwaka T P, Homback V, Torzewski J. C-reactive protein-mediated low density lipoprotein update by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194–1197, [INFOTRIEVE], [CSA]
- Wewers M D. Cytokines and macrophages. Cytokines in health and disease, D G Remick, J S Friedland. Marcel Dekker, New York 1997; 339–356
- Devaraj S, Xu D Y, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398–404, [INFOTRIEVE], [CROSSREF], [CSA]
- Pasceri V, Willerson J T, Yeh E T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165–2168, [INFOTRIEVE], [CSA]
- Sattar N, McCarey D W, Capell H, McInnes I B. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957–2963, [INFOTRIEVE], [CROSSREF], [CSA]
- Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis—results from a community based study. Ann Rheum Dis. 2004; 63: 952–955, [INFOTRIEVE], [CROSSREF], [CSA]
- Stenvinkel P. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. J Ren Nutr 2003; 13: 144–148, [INFOTRIEVE], [CROSSREF], [CSA]
- Beck J D, Offenbacher S. The association between periodontal diseases and cardiovascular diseases: a state-of-the-science review. Ann Periodontol 2001; 6: 9–15, [INFOTRIEVE], [CROSSREF], [CSA]
- Seymour R A, Steele J G. Is there a link between peridontal disease and coronary heart disease?. Br Dent J 1998; 184: 33–38, [INFOTRIEVE], [CROSSREF], [CSA]
- Kannel W B, McGee D L. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8–13, [INFOTRIEVE], [CSA]
- Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol 2002; 90(5A)27G–33G, [INFOTRIEVE], [CROSSREF], [CSA]
- Meyer O. Role of TNF-alpha and cytokines in the physiopathology of rheumatoid arthritis. Therapeutic perspectives. Bull Acad Natl Med 2003; 187: 935–954, [INFOTRIEVE], [CSA]
- Yeh E TH. CRP as a mediator of disease. Circulation 2004; 109: II-11–II-14, Suppl. II[CROSSREF], [CSA]
- Haffner S M, Greenberg A S, Weston W M, Chen H, Williams K, Freed M I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679–684, [INFOTRIEVE], [CROSSREF], [CSA]
- Janket S J, Qvarnstrom M, Meurman J H, Baird A E, Nuutinen P, Jones J A. Asymptomatic dental score and preventive coronary heart disease. Circulation 2004; 109: 1095–1100, [INFOTRIEVE], [CROSSREF], [CSA]
- Simmons E M, Himmelfarb J, Sezer M T, Chertow G M, Mehta R L, Paganini E P, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler T A, PICARD Study Group. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004; 65: 1357–1365, [INFOTRIEVE], [CROSSREF], [CSA]
- Ambrose J A, Barua R S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43: 1731–1737, [INFOTRIEVE], [CROSSREF], [CSA]
- Bohadana A, Tecluscu D, Martinet Y. Mechanisms of chronic airway obstruction. Respir Med 2004; 98: 139–151, [INFOTRIEVE], [CROSSREF], [CSA]
- Burke A, Fitzgerald G A. Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis 2003; 46: 79–90, [INFOTRIEVE], [CROSSREF], [CSA]
- Puranik R, Celermajer D S. Smoking and endothelial function. Prog Cardiovasc Dis 2003; 45: 443–458, [INFOTRIEVE], [CROSSREF], [CSA]
- Su Y, Cao W, Han Z, Block E R. Cigarette smoke extract inhibits angiogenesis of pulmonary artery endothelial cells: The role of calpain. Am J Physiol Lung Cell Mol Physiol 2004; 287: L794–800, [INFOTRIEVE], [CROSSREF], [CSA]
- Pittilo M R. Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol 2000; 81: 219–230, [CROSSREF], [CSA]
- Drost E M, Skwarski K M, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 2005; 60: 293–300, [INFOTRIEVE], [CROSSREF], [CSA]
- Wedzicha J A, Donaldson G C. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48: 1244–1214, [CSA]
- Opie L H, Commerford P J, Gersh B J, Pfeffer M A. Controversies in ventricular remodelling. Lancet 2006; 367: 356–367, [INFOTRIEVE], [CROSSREF], [CSA]
- Grimes D S, Hindle E, Dyer T. Respiratory infection and coronary heart disease: progression of a paradigm. Q J Med 2000; 93: 375–383, [CSA]
- Leinonen M, Saikku P. Infections and atherosclerosis. Scand Cardiovasc J 2000; 34: 12–20, [INFOTRIEVE], [CROSSREF], [CSA]
- Grayston J T, Kronmal R A, Jackson L A, Parisi A F, Muhlestein J B, Cohen J D, Rogers W J, Crouse J R, Borrowdale S L, Schron E, Knirsch C, ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637–45, [INFOTRIEVE], [CROSSREF], [CSA]
- Kiechl S, Werner P, Egger G, Oberhollenzer F, Mayr M, Xu Q, Poewe W, Willeit J. Active and passive smoking, chronic infections, and the risk of carotid atherosclerosis. Prospective results from the Bruneck study. Stroke 2002; 33: 2170–2176, [INFOTRIEVE], [CROSSREF], [CSA]
- Sauerwein H P, Schols A M. Glucose metabolism in chronic lung disease. Clin Nutr 2002; 21: 367–371, [INFOTRIEVE], [CROSSREF], [CSA]
- Kemppainen J, Tsuchida H, Stolen K, Karlsson H, Bjornholm M, Heinonen O J, Nuutila P, Krook A, Knuuti J, Zierath J R. Insulin signalling and resistance with chronic heart failure. J Physiol 2003; 550: 305–315, [INFOTRIEVE], [CROSSREF], [CSA]
- Sin D D, Anthonisen N R, Soriano J B, Agusti A G. Mortality in COPD: role of comorbidities. Eur Respir J 2006, (in press)[CSA]
- Laws P E, Spark J I, Cowled P A, Fitridge R A. The role of statins in vascular disease. Eur J Vasc Endovasc Surg 2004; 27: 6–16, [INFOTRIEVE], [CROSSREF], [CSA]
- Freed M I, Ratner R, Marcovina S M, Kreider M M, Biswas N, Cohen B R, Brunzell J D, Rosiglitazone Study 108 investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947–952, [INFOTRIEVE], [CROSSREF], [CSA]
- Nesto R. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabetic Med 2004; 2: 810–817, [CROSSREF], [CSA]
- National Institute of Health and Clinical Excellence, http://www.nice.org.uk/pdf/CG012_niceguideline.pdf (accessed February 2006)
- Sin D D, Lacy P, York E, Man S F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760–765, [INFOTRIEVE], [CROSSREF], [CSA]
- Calverley P. Are inhaled corticosteroids systemic therapy for chronic obstructive pulmonary disease?. Am J Respir Crit Care Med 2004; 170: 721–724, [INFOTRIEVE], [CROSSREF], [CSA]
- Pinto-Plata V M, Mullerova H, Toso J F, Feudjo-Tepie M, Soriano J B, Vessey R S, Celli B R. The C-reactive protein (C-RP) is elevated in patients with COPD but not in smokers (S) and non-smokers (NS) controls. CRP levels are influenced by use of MDI corticosteroids (CS). Am J Respir Crit Care Med 2004; 169: A839, [CSA]
- Barnes N C, Qiu Y S, Pavord I D, Parker D, Davis P A, Zhu J, Johnson M, Thomson N C, Jeffery P K. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med, 2006 Jan 19; [Epub ahead of print][CSA]
- Barnes P J. COPD: is there light at the end of the tunnel?. Curr Opin Pharmacol 2004; 4: 263–272, [INFOTRIEVE], [CROSSREF], [CSA]
- Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A, Maslen T K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–1303, [INFOTRIEVE], [CROSSREF], [CSA]
- Pauwels R A, Lofdahl C G, Laitinen L A, Schouten J P, Postma D S, Pride N B, Ohlsson S V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948–1953, [INFOTRIEVE], [CROSSREF], [CSA]
- Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902–1909, [CROSSREF], [CSA]
- Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–1823, [INFOTRIEVE], [CROSSREF], [CSA]
- Decramer M, Rutten-van Molken M, Dekhuijzen P N, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552–1560, [INFOTRIEVE], [CROSSREF], [CSA]
- Alsaeedi A, Sin D D, McAlister F A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59–65, [INFOTRIEVE], [CROSSREF], [CSA]
- Sutherland E R, Allmers H, Ayas N T, Venn A J, Martin R J. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58: 937–941, [INFOTRIEVE], [CROSSREF], [CSA]
- Sin D D, Tu J V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580–584, [INFOTRIEVE], [CSA]
- Sin D D, Man S F. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?. Eur Respir J 2003; 21: 260–266, [INFOTRIEVE], [CROSSREF], [CSA]
- Soriano J B, Vestbo J, Pride N B, Kiri V, Maden C, Maier W C. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20: 819–825, [INFOTRIEVE], [CROSSREF], [CSA]
- Kiri V A, Pride N B, Soriano J B, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005; 172: 460–464, [INFOTRIEVE], [CSA]
- Bourbeau J, Ernst P, Cockcoft D, Suissa S. Inhaled corticosteroids and hospitalisation due to exacerbation of COPD. Eur Respir J 2003; 22: 286–289, [INFOTRIEVE], [CSA]
- Fan V S, Bryson C L, Curtis J R, Fihn S D, Bridevaux P O, McDonell M B, Au D H. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death. Am J Respir Crit Care Med 2003; 168: 1488–1494, [INFOTRIEVE], [CROSSREF], [CSA]
- Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49–53, [INFOTRIEVE], [CROSSREF], [CSA]
- Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, TRial of Inhaled STeroids ANd long-acting beta-2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449–456, [INFOTRIEVE], [CROSSREF], [CSA]
- Hanania N A, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 μ g)/salmeterol (250 μ g) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834–843, [INFOTRIEVE], [CROSSREF], [CSA]
- Mahler D A, Wire P, Horstman D, Chang C N, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084–1091, [INFOTRIEVE], [CROSSREF], [CSA]
- Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81, [INFOTRIEVE], [CROSSREF], [CSA]
- Calverley P M, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912–919, [INFOTRIEVE], [CROSSREF], [CSA]
- Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634–639, [INFOTRIEVE], [CROSSREF], [CSA]
- The TORCH Study Group. The TORCH (Towards a Revolution in COPD Health) Survival Study protocol. Eur Respir J 2004; 24: 206–210, [CROSSREF], [CSA]